All treatments
Treatment
IRINOTECAN VIATRIS 20 mg/ml clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma.
This study looks at different treatment approaches for pancreatic cancer that has spread or is advanced. It combines standard chemotherapy with a new drug called OSE2101 or uses chemotherapy alone, after an initial treatment. The main goal is to see how long people live.
For: locally advanced or metastatic Pancreatic ductal adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
This study looks at different ways to give chemotherapy before surgery for pancreatic cancer. We want to see if a shorter or longer course of treatment works better in helping people live longer and preventing the cancer from growing.
For: pancreatic ductal adenocarcinomaItaly